U.S. Pharmacogenomics Markets

 

Regular Price: USD 3,950

Special Price USD 2,765

30% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

The U.S. Pharmacogenomics Market report focuses on the varying dynamics of the pharmacogenomics market. This report covers the Pharmacogenomics services, Gene-based Diagnostics, and Orphan Drugs segments. This report provides an in-depth analysis of the revenue sales forecasts for the market, drivers and restraints that affect the current and future markets, industry challenges and strategies, competitive, pricing and demand analysis and market and technology trends. The base year for this report is 2000.

Table of Contents

U.S. Pharmacogenomics Markets, Executive SummaryMarket OverviewPharmacogenomics and PolymorphismsThe Advantages of PharmacogenomicsMarket for PharmacogenomicsAnalysis by Major SegmentsOverviewService Market of PharmacogenomicsDiagnosticsOrphan DrugsOverall TrendsCompetitive AnalysisTechnologiesU.S. Pharmacogenomics Markets, Pharmacogenomics MarketResearch and ScopeObjectives and ValidationStructure and SegmentationForecast Period - MilestonesMethodology and DefinitionsResearch MethodologyList of DefinitionsList of AcronymsTotal Market AnalysisMarket OverviewMarket ChallengesMarket DriversMarket RestraintsMarket ForecastConclusionRecommendationsConcluding RemarksMarket Engineering AwardsMarketing Strategy Award - Orchid Biosciences Inc.Product Differentiation Innovation Award - Sequenom Inc.Product Launch Strategy Award - Orphan EuropeTechnology Innovation Award - ExonHit TherapeuticsTechnology Leadership Award - OmniViz Inc.U.S. Pharmacogenomics Markets, Pharmacogenomics ServicesService MarketOverview and DefinitionThe Present Market for Services and ForecastMaintaining Intellectual PropertyIntegrating Pharmacogenomics into the Development of DrugsAdopting Pharmacogenomics into the R&D ProcessMicroarrays MarketOverview and DefinitionCompetitive AssessmentAlternative to MicroarraysEvaluation of the Microarray MarketBioinformatics MarketOverview and DefinitionRole of Databanks in PharmacogenomicsBioinformatics SoftwareU.S. Pharmacogenomics Markets, Gene-Based DiagnosticsPresent Status of Diagnostics in PharmacogenomicsOverviewThe Market for the TPMT TestA Vast and Underestimated MarketFuture Status for Diagnostics in PharmacogenomicsThe Promise from PharmacogenomicsDiagnostics Model 1Diagnostics Model 2Forecasting the Winning ModelU.S. Pharmacogenomics Markets, Orphan DrugsBackgroundOverview and DefinitionPrecedent for Gene-Based DrugsLegislation Around Orphan DrugsMarket for Orphan DrugsImplications of Strategies Devised to Improve Orphan Drugs' ProfitabilityThe Present Market for Orphan DrugsRevenues for Orphan DrugsMarketing Models for Orphan Drugs"Airline Consortium" ModelOrganic Growth Model"Marginal Revenues" ModelThe Future for Orphan DrugsOverview and DefinitionsPharmacoeconomics Applied to Orphan DrugsPharmacogenomics Applied to Orphan DrugsInternational Dimension for Orphan Drug MarketEmerging Trends for Orphan Drugs




Related Research

Release Date : 26-Sep-17

Region : North America

Release Date : 25-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.